Net loss narrowed to $26.3 million in Q3 2025 from $57.8 million in Q3 2024, with EPS improving to -$0.43 from -$0.95.
R&D expenses dropped to $17.9 million from $47.8 million YoY due to BEACON-IPF discontinuation.
G&A expenses decreased to $10.3 million from $14.3 million.
Cash, cash equivalents, and short-term investments totaled $243.3 million as of September 30, 2025.
BEACON-IPF Phase 2b/3 trial close-out completing in Q4 2025 with results for future publication.
PLN-101095 Phase 1 trial completed enrollment; full data expected by end of 2025, showing 50% objective response rate in checkpoint-resistant patients.
EPS beat consensus estimate of -$0.52 or -$0.53.
45% workforce reduction and restructuring completed, lowering operating expenses.